FDA approves first treatment for children with LEMS, a rare autoimmune disorder
The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.…
Read More...
Read More...
